{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/API.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"API.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"API.AU\",,,,,undefined,":{"symbol":"API.AU","market":"AU","secType":"STK","nameCN":"Australian Pharma Industries","latestPrice":1.53,"timestamp":1744869600000,"preClose":1.53,"halted":0,"volume":0,"delay":0,"nameEN":"Australian Pharma Industries","floatShares":396917399,"shares":492656035,"eps":0.002795,"marketStatus":"Market Closed","change":0,"latestTime":"04-17 16:00:00 AEST","open":1.53,"high":1.53,"low":1.53,"amount":5184735.1000092,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.002795,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":1.53,"dividendRate":0.022876,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":1.318654687580577,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"API.AU\",,,,,undefined,":{"symbol":"API.AU","floatShares":396917399,"roa":"2.59%","roe":"0.26%","lyrEps":0.002795,"volumeRatio":1.318654687580577,"shares":492656035,"dividePrice":0.035,"high":1.53,"amplitude":0,"preClose":1.53,"low":1.53,"week52Low":1.53,"pbRate":"1.72","week52High":1.53,"institutionHeld":0,"latestPrice":1.53,"eps":0.002795,"divideRate":0.022876,"volume":0,"delay":0,"ttmEps":0.002795,"open":1.53,"prevYearClose":1.5,"prevWeekClose":1.5,"prevMonthClose":1.5,"prevQuarterClose":1.5,"fiveDayClose":1.5,"twentyDayClose":1.5,"sixtyDayClose":1.5},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/API.AU\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"API.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524237249","title":"Jiangsu Sinopep-Allsino Biopharmaceutical Gets EU Export Nod for Type 2 Diabetes Drug API","url":"https://stock-news.laohu8.com/highlight/detail?id=2524237249","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524237249?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:00","pubTimestamp":1743678015,"startTime":"0","endTime":"0","summary":"Jiangsu Sinopep-Allsino Biopharmaceutical  obtained approval to export tirzepatide as an active pharmaceutical ingredient  to the European Union, according to a Thursday filing with the Shanghai Stock Exchange.Sinopep-Allsino's factory in Lianyungang passed the EU's good manufacturing practice compliance for export, the filing said.Tirzepatide is indicated for type 2 diabetes.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4503","API","BK7103","BK4023","BK4156","BK6520","BK4551","BK0239","BK6100","API.AU","BK4535","688076","OTX.SI"],"gpt_icon":0},{"id":"2518829472","title":"Hunan Warrant Pharmaceutical to Invest Up to 500 Million Yuan in API Manufacturing Base","url":"https://stock-news.laohu8.com/highlight/detail?id=2518829472","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518829472?lang=en_us&edition=fundamental","pubTime":"2025-03-10 16:07","pubTimestamp":1741594054,"startTime":"0","endTime":"0","summary":"Hunan Warrant Pharmaceutical (SHA:688799) is planning to invest up to 500 million yuan in the phase two expansion of its high-end active pharmaceutical ingredient (API) and intermediate green manufact","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4503","API","BK7103","BK4023","BK6520","BK4551","BK0239","BK6100","API.AU","BK4535","OTX.SI","688799"],"gpt_icon":0},{"id":"2514346627","title":"Guobang Pharma Subsidiary Gains Approval for Domestic Production of Cefuroxime Axetil API","url":"https://stock-news.laohu8.com/highlight/detail?id=2514346627","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514346627?lang=en_us&edition=fundamental","pubTime":"2025-02-28 17:46","pubTimestamp":1740735996,"startTime":"0","endTime":"0","summary":"Guobang Pharma's  subsidiary, Zhejiang Dongying, received approval from China's National Medical Products Administration to domestically produce its Cefuroxime Axetil Active Pharmaceutical Ingredient , according to a Friday filing with the Shanghai Bourse.The antibiotic treats respiratory, skin, and gonococcal infections. The API is also certified by the European EDQM.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4551","BK7103","OTX.SI","API.AU","BK4023","BK0239","BK6100","BK6520","API","BK4503","BK4535","605507"],"gpt_icon":0},{"id":"2513126870","title":"Zhejiang Jianfeng Group Unit Secures Approval for API Market Entry","url":"https://stock-news.laohu8.com/highlight/detail?id=2513126870","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513126870?lang=en_us&edition=fundamental","pubTime":"2025-02-21 18:38","pubTimestamp":1740134287,"startTime":"0","endTime":"0","summary":"Zhejiang Jianfeng Group (SHA:600668) subsidiary Jianfeng Pharmaceutical obtained approval from China's drug administrator for active pharmaceutical ingredient (API) roxadustat.The approval is expected to expand the company's business scope, according to a Friday filing with the Shanghai bourse.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4503","BK0186","BK6520","BK0235","OTX.SI","API.AU","API","BK4551","BK7103","BK0188","BK6100","600668","BK4023","BK4535"],"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/API.AU\",params:#limit:5,,,undefined,":[{"date":"2022-10-20","symbol":"API.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1666220400000,"name":null,"time":"","dateTimestamp":1666184400000,"actualEps":null},{"date":"2022-04-21","symbol":"API.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1650499200000,"name":null,"time":"","dateTimestamp":1650463200000,"actualEps":null},{"market":"AU","date":"2022-04-04","symbol":"API.AU","reason":null,"defaultRemindTime":1649030400000,"announcedDate":"2022-04-01","type":"delisting","dateTimestamp":1648994400000},{"market":"AU","date":"2022-03-24","symbol":"API.AU","amount":0.03,"defaultRemindTime":1648076400000,"name":"Australian Pharma Industries","recordDate":"2022-03-29","payableDate":"2022-03-25","currency":"AUD","type":"dividend","dateTimestamp":1648040400000},{"market":"AU","date":"2021-11-11","symbol":"API.AU","amount":0.02,"defaultRemindTime":1636585200000,"name":"Australian Pharma Industries","recordDate":"2021-12-15","payableDate":"2021-11-12","currency":"AUD","type":"dividend","dateTimestamp":1636549200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"API.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-11-11","recordDate":"2020-11-12","paymentDate":"2020-12-15","value":0.02,"currency":"AUD"},{"executeDate":"2021-05-06","recordDate":"2021-05-07","paymentDate":"2021-06-04","value":0.015,"currency":"AUD"},{"executeDate":"2021-11-11","recordDate":"2021-11-12","paymentDate":"2021-12-15","value":0.02,"currency":"AUD"},{"executeDate":"2022-03-24","recordDate":"2022-03-25","paymentDate":"2022-03-29","value":0.03,"currency":"AUD"}]}}